| Literature DB >> 32164550 |
Justina Kacerauskiene1, Meile Minkauskiene2, Tahir Mahmood3, Egle Bartuseviciene2, Dalia R Railaite2, Arnoldas Bartusevicius2, Mindaugas Kliucinskas2, Laima Maleckiene2, Jonas Ulevicius2, Laura Liubiniene2, Kastytis Smigelskas2, Kornelija Maciuliene4, Grazina Drasutiene4, Diana Ramasauskaite4, Ruta J Nadisauskiene2.
Abstract
BACKGROUND: To evaluate the role of the quality improvement course (QIC) to reduce the caesarean section (CS) rate among nulliparas (Robson groups 1 and 2) and to find out which group of women have reduced the CS rate following attendance at the course.Entities:
Keywords: Caesarean section; Intervention; Nulliparas; Quality improvement course; Rate
Mesh:
Substances:
Year: 2020 PMID: 32164550 PMCID: PMC7069017 DOI: 10.1186/s12884-020-2806-5
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
The 10-group classification system
| No. | Group |
|---|---|
| Group 1 | Nulliparous, single cephalic, 37 weeks, in spontaneous labour |
| Group 2A | Nulliparous, single cephalic, 37 weeks, induced labour |
| Group 2B | Nulliparous, single cephalic, 37 weeks, CS before labour |
| Group 3 | Multiparous (excluding prev. CS), single cephalic, 37 weeks, in spontaneous labour |
| Group 4A | Multiparous (excluding prev. CS), single cephalic, 37 weeks, induced labour |
| Group 4B | Multiparous (excluding prev. CS), single cephalic, 37 weeks, CS before a labour |
| Group 5A | Previous CS, single cephalic, 37 weeks, induced labour |
| Group 5B | Previous CS, single cephalic, 37 weeks, CS before labour |
| Group 5C | Previous CS, single cephalic, 37 weeks, in spontaneous labour |
| Group 6 | All nulliparous breeches |
| Group 7 | All multiparous breeches (including prev. CS) |
| Group 8 | All multiple pregnancies (including prev. CS) |
| Group 9 | All abnormal lies (including prev. CS) |
| Group 10 | All single cephalic, ≤ 36 weeks (including prev. CS) |
Socio-demographic and personal data
| 2014 | 2016 | ||
|---|---|---|---|
| urban, n (%) | 2886 (80.5) | 2967 (81.8) | |
| rural, n (%) | 699 (19.5) | 661 (18.2) | |
| basic, primary and secondary, n (%) | 1649 (46.0) | 1600 (44.1) | |
| higher, n (%) | 1936 (54.0) | 2028 (55.9) | |
| single, n (%) | 1089 (30.4) | 1049 (28.9) | |
| married, n (%) | 2496 (69.6) | 2579 (71.1) | |
| < 20, n (%) | 1142 (31.9) | 1016 (28.0) | |
| 20–34, n (%) | 2224 (62.0) | 2377 (65.5) | |
| ≥ 35, n (%) | 219 (6.1) | 235 (6.5) | |
| 124 (3.5) | 122 (3.4) | ||
The CS rate in 2014 and 2016
| Number of CSs in the total number of women in each group | Relative group size (%) | CS rate in each group (%) | Absolute contribution to the overall CS rate (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2014 | 2016 | 2014 | 2016 | 2014 | 2016 | 2014 | 2016 | |||
| Group 1 | 340/2698 | 300/2590 | 77.0 2698/3502 | 73.5 2590/3526 | 12.6 | 11.6 | 9.7340/3502 | 8.5300/3526 | ||
| Group 2 | 326/804 | 293/936 | 23.0804/3502 | 26.5936/3526 | 40.5 | 31.3 | 9.3326/3502 | 8.3293/3526 | ||
| Group 2A | 220/698 | 211/852 | 19.9698/3502 | 24.2852/3526 | 31.5 | 24.8 | 6.3220/3502 | 6211/3526 | ||
| Group 2B | 106/106 | 82/82 | 3.0106/3502 | 2.3 82/3526 | 100 | 100 | – | 3.0106/3502 | 2.3 82/3526 | |
| Group 1 and 2 | 665/3502 | 593/3526 | 19.0 | 16.8 | 665/3502 | 593/3526 | ||||
Indications for CS among women in group 1
| Indication | Absolute contribution to the CS rate in group 1, %, 2014 | Absolute contribution to the CS rate in group 1, %, 2016 | Absolute contribution to the overall CS rate, %, 2014 | Absolute contribution to the overall CS rate, %, 2016 | ||
|---|---|---|---|---|---|---|
| 15.9 54/340 | 17.3 53/294 | 1.5 54/3502 | 1.4 53/3526 | |||
| 74.1252/340 | 75.5225/294 | 7.2252/3502 | 6.3225/3526 | |||
| CCD without oxytocin | 10.0 34/340 | 10.5 31/294 | 1.0 34/3502 | 0.9 31/3526 | ||
| CCD with oxytocin | 20.0 68/340 | 16.0 47/294 | 2.9 68/3502 | 1.3 47/3526 | ||
| ICD without oxytocin | 6.2 21/340 | 7.1 21/294 | 0.6 21/3502 | 0.6 21/3526 | ||
| ICD with oxytocin | 27.9 95/340 | 33.0100/294 | 2.7 95/3502 | 2.8100/3526 | ||
| FC with oxytocina | 10.0 34/340 | 8.8 26/294 | 1.0 34/3502 | 0.7 26/3526 | ||
| 10.0 34/340 | 7.1 22/294 | 1.0 34/3502 | 0.6 22/3526 | |||
| 9.7340/3502 | 8.5300/3526 |
a“FC with oxytocin” was attributed to “dystocia” because the reason why oxytocin was administered was dystocia
Peculiarities of deliveries when the indication for CS is “dystocia”
| 2014 | 2016 | ||
|---|---|---|---|
| Cervical dilatation at the moment of oxytocin administration, cm (mean, SD) | 5.7 (2.21) | 5.07 (2.03) | |
| Waiting time passed before making the decision to perform a CS because of dystocia, min (mean, SD) | 87.8 (38.7) | 107.62 (73.21) | |
| Cervical dilatation at the moment of oxytocin administration, cm (mean, SD) | 4.1 (2.24) | 4.38 (2.47) | |
| Cervical dilatation at the moment of the decision to perform a CS because of dystocia, cm (mean, SD) | 5.38 (2.61) | 6.16 (2.58) | |
| Waiting time passed before the decision to perform CS because of dystocia, min (mean, SD) | 217.21 (164.47) | 204.82 (162.01) | |
Indications for operations in women with elective CSs
| Indication | Absolute contribution to the CS rate in group 2B, %, 2014 | Absolute contribution to the CS rate in group 2B, %, 2016 | p value | Absolute contribution to the overall CS rate, %, 2014 | Absolute contribution to the overall CS rate, %, 2016 | p value |
|---|---|---|---|---|---|---|
| Placental and umbilical cord pathology | 10.4 11/106 | 4.9 4/82 | 0.3 11/3502 | 0.1 4/3526 | ||
| Fetus related conditions | 11.3 12/106 | 15.9 13/82 | 0.3 12/3502 | 04 13/3526 | ||
| Maternal diseases | 49.0 52/106 | 61.0 50/82 | 1.5 52/3502 | 1.4 50/3526 | ||
| Suspected fetal macrosomia | 9.4 10/106 | 4.9 4/82 | 0.3 10/3502 | 0.1 4/3526 | ||
| Preeclampsia | 4.7 5/106 | 7.3 6/82 | 0.1 5/3502 | 0.2 6/3526 | ||
| Post-term pregnancy | 15.1 16/106 | 6.1 5/82 | 0.5 16/3502 | 0.1 5/3526 | ||
| Total | 3.0106/3502 | 2.3 82/3526 |
Newborn related outcomes
| Indicator | 2014 | 2016 | |
|---|---|---|---|
| < 3000 g, n (%) | 429 (12.0) | 371 (10.2) | |
| 3000–3999 g, n (%) | 2691 (75.1) | 2721 (75.0) | |
| ≥ 4000 g, n (%) | 465 (13.0) | 536 (14.8) | |
| ≤ 7, n (%) | 6 (0.2) | 26 (0.7) | |
| ≥ 8, n (%) | 3579 (99.8) | 3602 (99.3) | |
| antepartum deaths, n | 7 | 8 | |
| intrapartum deaths, n | 0 | 2 | |
| early neonatal deaths, n | 4 | 4 | |
| perinatal mortality | 3.1/1000 | 3.9/1000 | |